These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 20355157)

  • 1. Screening for the calstabin-ryanodine receptor complex stabilizers JTV-519 and S-107 in doping control analysis.
    Thevis M; Beuck S; Thomas A; Kohler M; Schlörer N; Vajiala I; Schänzer W
    Drug Test Anal; 2009 Jan; 1(1):32-42. PubMed ID: 20355157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electron ionization mass spectrometry of the ryanodine receptor-based Ca(2+)-channel stabilizer S-107 and its implementation into routine doping control.
    Thevis M; Beuck S; Thomas A; Fusshöller G; Sigmund G; Schlörer N; Rodchenkov G; Schäfer M; Schänzer W
    Rapid Commun Mass Spectrom; 2009 Aug; 23(15):2363-70. PubMed ID: 19575395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doping control analysis of emerging drugs in human plasma - identification of GW501516, S-107, JTV-519, and S-40503.
    Thevis M; Beuck S; Thomas A; Kortner B; Kohler M; Rodchenkov G; Schänzer W
    Rapid Commun Mass Spectrom; 2009 Apr; 23(8):1139-46. PubMed ID: 19280612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mass spectrometric characterization of a prolyl hydroxylase inhibitor GSK1278863, its bishydroxylated metabolite, and its implementation into routine doping controls.
    Thevis M; Milosovich S; Licea-Perez H; Knecht D; Cavalier T; Schänzer W
    Drug Test Anal; 2016 Aug; 8(8):858-63. PubMed ID: 26361079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the collision-induced dissociation of adipoR agonists after electrospray ionization and their implementation in sports drug testing.
    Dib J; Schlörer N; Schänzer W; Thevis M
    J Mass Spectrom; 2015 Feb; 50(2):407-17. PubMed ID: 25800023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging.
    Andersson DC; Betzenhauser MJ; Reiken S; Meli AC; Umanskaya A; Xie W; Shiomi T; Zalk R; Lacampagne A; Marks AR
    Cell Metab; 2011 Aug; 14(2):196-207. PubMed ID: 21803290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Calstabin1 depletion on calcium transients and energy utilization in muscle fibers and treatment opportunities with RyR1 stabilizers.
    Breckner A; Ganz M; Marcellin D; Richter J; Gerwin N; Rausch M
    PLoS One; 2013; 8(11):e81277. PubMed ID: 24303040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for metabolically stable aryl-propionamide-derived selective androgen receptor modulators for doping control purposes.
    Thevis M; Kamber M; Schänzer W
    Rapid Commun Mass Spectrom; 2006; 20(5):870-6. PubMed ID: 16470709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanding sports drug testing assays: mass spectrometric characterization of the selective androgen receptor modulator drug candidates RAD140 and ACP-105.
    Thevis M; Piper T; Beuck S; Geyer H; Schänzer W
    Rapid Commun Mass Spectrom; 2013 Jun; 27(11):1173-82. PubMed ID: 23650030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doping control analysis of tricyclic tetrahydroquinoline-derived selective androgen receptor modulators using liquid chromatography/electrospray ionization tandem mass spectrometry.
    Thevis M; Kohler M; Thomas A; Schlörer N; Schänzer W
    Rapid Commun Mass Spectrom; 2008 Aug; 22(16):2471-8. PubMed ID: 18634123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure.
    Wehrens XH; Lehnart SE; Reiken S; van der Nagel R; Morales R; Sun J; Cheng Z; Deng SX; de Windt LJ; Landry DW; Marks AR
    Proc Natl Acad Sci U S A; 2005 Jul; 102(27):9607-12. PubMed ID: 15972811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remodeling of ryanodine receptor complex causes "leaky" channels: a molecular mechanism for decreased exercise capacity.
    Bellinger AM; Reiken S; Dura M; Murphy PW; Deng SX; Landry DW; Nieman D; Lehnart SE; Samaru M; LaCampagne A; Marks AR
    Proc Natl Acad Sci U S A; 2008 Feb; 105(6):2198-202. PubMed ID: 18268335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass spectrometry-based characterization of new drugs and methods of performance manipulation in doping control analysis.
    Thevis M; Thomas A; Kohler M; Beuck S; Möller I; Schäfer M; Rodchenkov G; Yin S; Loo JA; Geyer H; Schänzer W
    Eur J Mass Spectrom (Chichester); 2010; 16(3):301-12. PubMed ID: 20530837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of N-desmethyl- and N-bisdesmethyl metabolites of Sibutramine in doping control analysis using liquid chromatography-tandem mass spectrometry.
    Thevis M; Sigmund G; Schiffer AK; Schänzer W
    Eur J Mass Spectrom (Chichester); 2006; 12(2):129-36. PubMed ID: 16723754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls.
    Thevis M; Möller I; Thomas A; Beuck S; Rodchenkov G; Bornatsch W; Geyer H; Schänzer W
    Anal Bioanal Chem; 2010 Apr; 396(7):2479-91. PubMed ID: 19946680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of the in vitro metabolism of the emerging drug candidate S107 for doping-preventive purposes.
    Beuck S; Schänzer W; Thevis M
    J Mass Spectrom; 2011 Feb; 46(2):112-30. PubMed ID: 21254313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mechanism of ryanodine receptor modulation by FKBP12/12.6, protein kinase A, and K201.
    Blayney LM; Jones JL; Griffiths J; Lai FA
    Cardiovasc Res; 2010 Jan; 85(1):68-78. PubMed ID: 19661110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for 2-quinolinone-derived selective androgen receptor agonists in doping control analysis.
    Thevis M; Kohler M; Maurer J; Schlörer N; Kamber M; Schänzer W
    Rapid Commun Mass Spectrom; 2007; 21(21):3477-86. PubMed ID: 17985352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring phosphodiesterase-4 inhibitors using liquid chromatography/(tandem) mass spectrometry in sports drug testing.
    Thevis M; Krug O; Schänzer W
    Rapid Commun Mass Spectrom; 2013 May; 27(9):993-1004. PubMed ID: 23592202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fragmentation studies of SIRT1-activating drugs and their detection in human plasma for doping control purposes.
    Höppner S; Schänzer W; Thevis M
    Rapid Commun Mass Spectrom; 2013 Jan; 27(1):35-50. PubMed ID: 23239315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.